MK-677 vs Sermorelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicMK-677Sermorelin
What it is

Not a peptide: a small molecule often looked up alongside peptides5,6

A synthetic small-molecule growth hormone secretagogue, recorded by FDA’s substance registry as ibutamoren mesylate and also called MK-677 and MK-0677.5,6

Growth hormone-releasing factor (human) fragment 1 to 29, amidated, also recorded as groliberin, according to FDA’s substance registry.7

FDA status

Not FDA-approved

No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1,2

No FDA approval is reported in the sources reviewed here. FDA lists ibutamoren mesylate in category 2 of both of its interim compounding policies, for substances that may present significant safety risks, and its advisory committee voted 13 to 1 in 2024 against adding it to the compounding list.1,2

Is MK-677 FDA-approved?

Not FDA-approved

FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness3,4

Not FDA-approved. FDA withdrew the approvals of both Geref applications, NDA 019863 and NDA 020443, effective June 18, 2009, after the maker discontinued them, according to a 2013 Federal Register notice.3,4

Is sermorelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.8

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. MK-677 is not among them.8,9

Not among the six peptides the policy lists.8

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Sermorelin is not among them.8,9

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists ibutamoren mesylate in category 2 under both interim compounding policies: for pharmacies (section 503A) since September 29, 2023, and for outsourcing facilities (section 503B) since December 29, 2022.1

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list sermorelin, either in category 2 or among withdrawn nominations.1

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial A randomized, double-blind, multicenter trial in 563 people with mild to moderate Alzheimer disease, which found no difference from placebo on any measure of disease progression over 12 months.10
  • Controlled human trial A randomized, double-blind, placebo-controlled trial in 123 older adults recovering from hip fracture, terminated early because of a safety signal of congestive heart failure.11
  • Animal or laboratory research A rat study showing that MK-0677 activates growth hormone-regulating nerve cells in the hypothalamus.6

Limited human data

  • Small, short, or incompletely reported human study An open-label, multicenter study in 110 previously untreated children with growth hormone deficiency, without a comparison group, reported by the Geref International Study Group (1996).12
Records collected

2 ClinicalTrials.gov records and 4 PubMed records collected

0 ClinicalTrials.gov records and 2 PubMed records collected

Area of study

Hormones5,6

Hormones3

Latest dated events
  1. FDA’s Pharmacy Compounding Advisory Committee votes 13 to 1 against placing ibutamoren mesylate on the 503A bulks list.2
  2. FDA places ibutamoren mesylate in category 2 under its 503A interim compounding policy, according to its safety-risk page.1
  3. FDA places ibutamoren mesylate in category 2 under its 503B interim compounding policy, according to its safety-risk page.1
  1. FDA publishes its determination that Geref was not withdrawn from sale for reasons of safety or effectiveness.3
  2. FDA’s withdrawal of both Geref approvals takes effect, at the maker’s request, according to FDA’s 2013 notice.3
  3. FDA approves Geref for growth hormone deficiency in children, NDA 020443.3,4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (March 4, 2013) · FR Doc. 2013-04827 ↗

    Federal Register · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  5. 5
    Ibutamoren mesylate (MK-677) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  6. 6
    The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo (1998) · PMID 9535057 ↗

    Journal of Neuroendocrinology · Official source · Source checked November 16, 2026

  7. 7
    Sermorelin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  10. 10
    Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (2008) · PMID 19015485 ↗

    Neurology · Official source · Source checked November 16, 2026

  11. 11
    MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study (2011) · PMID 21067829 ↗

    Archives of Gerontology and Geriatrics · Official source · Source checked November 16, 2026

  12. 12
    Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group (1996) · PMID 8772599 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026